List of publications

  1. Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME, El Kassas M, Bedossa P, Carrat F, Fontanet A, Esmat G. Comparisoon of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. Journal of Viral Hepatitis. 2014 Jul 30. doi: 10.1111/jvh.12285. [Epub ahead of print]. Abstract
  2. Mohsen A, Bernier A, LeFouler L, Delarocque-Astagneau E, El-Daly M, El-Kafrawy S, El-Mango S, Abdel-Hamid M, Gadallah M, Esmat G, Mohamed MK, Fontanet A. Hepatitis C virus acquisition qmong Egyptians: analysis of a 10-year surveillance of acute hepatitis C. Tropical Medicine and International Health. 2015 Jan;20(1):89-97. doi: 10.1111/tmi.12410. Epub 2014 Oct 22. Abstract
  3. Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, Abdel-Hamid M, Doss W, Esmat G, Mohamed MK, Fontanet A. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Global Health 2014; 2: e541-49. Abstract
  4. Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A, Pawlotsky JM, Hézode C, Rosa I, Renard P, Mohamed MK, Bonnard P, Izopet J, Mallet V, Pol S, Albert ML, Fontanet A. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in Hepatitis C virus infection, J Hepatol. 2014; 61(4):770-6. doi: 10.1016/j.jhep.2014.05.040. Abstract

  5. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nature Reviews Gastroenterol Hepatol. 2014;11:28-35. Abstract

  6. Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y. Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Med Res Methodol. 2014;14:39. Abstract

  7. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y. Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. Clin Infect Dis. 2014;58:1064-71. Abstract

  8. Duffy D, Mamdouh R, Laird M, Soneson C, Le Fouler L, El-Daly M, Casrouge A, Decalf J, Abbas A, Eldin NS, Fontes M, Abdel-Hamid M, Mohamed MK, Rafik M, Fontanet A, Albert ML. The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. Hepatology. 2014;59:1273-82. Abstract

  9. Féray C, Bouscaillou J, Falissard B, Mohamed MK, Arafa N, Bakr I, El-Hoseiny M, Daly ME, El-Kafrawy S, Plancoulaine S, Abdel-Hamid M, Thiers V, Fontanet A. A novel method to identify routes of hepatitis C virus transmission. PLoS One. 2014;9:e86098. Abstract

  10. Munier A, Marzouk D, Abravanel F, El-Daly M, Taylor S, Mamdouh R, Eldin WS, El-Arab HE, Sos DG, Momen M, Okasha O, Le Fouler L, El-Hosini M, Izopet J, Rafik M, Albert ML, Abdel-Hamid M, Mohamed MK, Delarocque-Astagneau E, Fontanet A. Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, Egypt. PLoS One. 2013;8(2):e57835. Abstract

  11. Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR, Kamal M, Esmat G, Bonnard P, Fontanet A, Rafik M, Albert ML. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine. 2013;63:105-12. Abstract

  12. Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat. 2013 Apr;20(4):294-6. Abstract

  13. Pedergnana V, Abdel-Hamid M, Guergnon J, Mohsen A, Le Fouler L, Theodorou I, Mohamed MK, Fontanet A, Plancoulaine S, Abel L. Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virus. PLoS ONE. 2012;7(6):e38578. Abstract

  14. Delarocque-Astagneau E, Abravanel F, Moshen A, Le Fouler L, Gad RR, El-Daly M, Ibrahim EM, El-Aidy S, Lashin T, El-Hoseiny M, Izopet J, Mohamed MK, Fontanet A, Abdel-Hamid M. Epidemiological and virological characteristics of symptomatic acute hepatitis E in Greater Cairo, Egypt. Clin Microbiol Infect. 2012;18(10):982-8. Abstract

  15. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012 ;19(8):560-7. Abstract
  16. Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep. 2012;61(29):545-9. Abstract

  17. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011;121(1):308-17. Abstract

  18. Vignier N, Esmat G, Sharkawy AE, Hassany M, Bonnard P, Delarocque-Astagneau E, Said M, Raafat R, El-Hoseiny M, Fontanet A, Mohamed MK, Vray M. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. J Viral Hepat. 2011;18(7):e358-365. Abstract

  19. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010;59(8):1135-40. Abstract

  20. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, Mohsen A, Mostafa A, Delarocque-Astagneau E, Abdel-Hamid M, Fontanet A, Mohamed MK, Thiers V. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut. 2010;59(11):1554-60. Abstract

  21. Mansour H, Laird ME, Saleh R, Casrouge A, Eldin NS, El Kafrawy S, Hamdy M, Decalf J, Rosenberg BR, Fontanet A, Abdel-Hamid M, Mohamed MK, Albert ML, Rafik M. Circulating plasmacytoid dendritic cells in acutely infected patients with hepatitis C virus genotype 4 are normal in number and phenotype. J Infect Dis. 2010;202(11):1671-5. Abstract

  22. Schwarzinger M, Mohamed MK, Gad RR, Dewedar S, Fontanet A, Carrat F, Luchini S. Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health. 2010;10:773. Abstract
  23. Mostafa A, Taylor SM, El-Daly M, El Hoseiny M, Bakr I, Arafa N, Thiers V, Rimlinger F, Abdel-Hamid M, Fontanet A, Mohamed MK. Is the Hepatitis C Virus epidemic over in Egypt? : Incidence and risk factors of new hepatitis C virus infections. Liver Int. 2010 avr;30(4):560-6. Abstract

  24. Paez Jimenez A, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, Elsaid N, Rekacewicz C, El-Hoseiny M, El-Daly M, Abdel-Hamid M, Fontanet A. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One. 2009 Sep 28;4(9):e7193. Abstract

  25. Laouénan C, Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Abdel-Hamid M, Rekacewicz C, Obach D, Fontanet A, Abel L. Evidence for a dominant major gene conferring predisposition to hepatitis C virus infection in endemic conditions. Hum Genet. 2009 Nov;126(5):697-705. Abstract

  26. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009;81:1576-83. Abstract

  27. Paez Jimenez A, El-Din NS, El-Hoseiny M, El-Daly M, Abdel-Hamid M, El Aidi S, Sultan Y, El-Sayed N, Mohamed MK, Fontanet A. Community transmission of hepatitis B virus in Egypt: results from a case-control study in Greater Cairo. Int J Epidemiol. 2009;38:757-65. Abstract

  28. Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El-Kafrawy S, El Aidi S, Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK. Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One. 2008;3:e4085. Abstract

  29. Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Rekacewicz C, Trégouët DA, Obach D, El Daly M, Thiers V, Féray C, Abdel-Hamid M, Abel L, Fontanet A. Dissection of familial correlations in Hepatitis C Virus (HCV) seroprevalence suggests evidence for intrafamilial viral transmission and genetic predisposition to infection. Gut. 2008;57:1268-74. Abstract

  30. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, Zalata K, Abdel-Hamid M, Fontanet A, Mohamed MK, Esmat G. Predictors of sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int. 2008;28:1112-9. Abstract

  31. Abdoul H, Mallet V, Pol S, Fontanet A. Serum alpha-fetoprotein predicts treatment in chronic hepatitis C patients regardless of HCV genotype. PLoS ONE. 2008 Jun 11;3(6):e239. Abstract

  32. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, El Hoseiny M, Zalata K, Abdel-Hamid M, Bedossa P, Pol S, Mohamed MK, Fontanet A. Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007;12:797-803. Abstract

  33. Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and HCV infection in rural Egypt. Gut. 2007;56:1105-10. Abstract

  34. Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A. HCV-related morbidity in a rural community of Egypt. J Med Virol. 2006;78:1185-9. Abstract

  35. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat E, Abdel-Hamid M, Mohamed M, Fontanet A. Higher clearance of HCV infection in females compared to males. Gut. 2006;55:1183-7. Abstract

  36. Deuffic-Burban S, Mohamed MK, Larouzé B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006;44:455-61. Abstract

  37. Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A. Changing pattern of HCV spread in rural areas of Egypt. J Hepatol. 2005;43:418-24. Abstract

  38. El Gaafary MM, Rekacewicz C, Abdel-Rahman AG, Allam MF, El Hosseiny M, Abdel Hamid M, Colombani F, Sultan Y, El-Aidy S, Fontanet A, Mohamed MK. Surveillance of acute hepatitis C in Cairo, Egypt. J Med Virol. 2005;76:520-5. Abstract

  39. Schwarzinger M, Dewedar S, Rekacewicz C, Mahmoud K, Fontanet A, Carrat F, Mohamed MK. Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology. 2004;40:1434-1441. Abstract




Introduction of Sofosbuvir in Egypt

In July 2014, Gilead and the Egyptian government signed an agreement for a treatment expansion of Sovaldi® (Sofosbuvir). Read more

Scientific Advisory Board Meeting

The Scientific Advisory Board Meeting was held in Paris February 15-16, 2013.

Read more

fp7_01fp7_02 This project is funded
by the European Union